Telix Pharmaceuticals Limited

Telix today welcomes the announcement by the United States (U.S.) Centers for Medicare & Medicaid Services (CMS) that it will pay separately for specialised diagnostic radiopharmaceuticals for Medicare Fee for Service patients in the hospital outpatient setting, beyond the transitional pass-through payment period. This is a significant decision for patients and hospitals, with the change facilitating equitable access to advanced imaging agents for all patients into the future. The new separate payment rule will apply to Illuccix® after its pass-through status expires. It will also apply to Telix’s pipeline of investigational diagnostic imaging agents – TLX007-CDx, a new product for prostate cancer imaging, TLX250-CDx for kidney cancer imaging, and TLX101-CDx for brain cancer (glioma) imaging – if approved and reimbursed under CMS, and after pass-through expires. Read more on our website here: https://lnkd.in/gc2wVapM

Telix today announces a partnership with California-based Subtle Medical for AI-powered PET imaging with Telix’s commercial PSMA-PET product, Illuccix® (68Ga-PSMA-11).  The SubtlePET™ software solution is a proprietary FDA-cleared deep-learning algorithm that allows for faster PET scanning (up to 75% time savings) without compromising image quality. The technology represents a significant advancement in the field, offering numerous benefits to patients, physicians, and medical facilities. Through this partnership we are excited to add an innovative AI product to enhance the value of Illuccix for our customers and the patients they serve. Swipe below to learn more and read the full announcement here: https://lnkd.in/g48u6Dtx

Telix is pleased to support AusBiotech's #AusBio2024 conference taking place this week in Melbourne, Australia. As part of Australia's biggest week in biotech: ⚛️Telix Chief Scientist, Dr Michael Wheatcroft and SVP Investor Relations and Corporate Communications, Kyahn Williamson, will take part in a Telix-sponsored session on ‘The rise of radiopharmaceuticals: How Australian biotech is at the forefront of this resurgence’. ⚛️Telix Operations Director – APAC, Dr Charlotte Werden (née Krenus), will take part in the CSIRO Biomedical Manufacturing hosted panel on ‘Regulated manufacture of bioconjugates for clinical use’. To see the full program and to register, visit the Ausbiotech website here: https://lnkd.in/eBB_WT3

Telix today announces that the U.S. FDA has accepted and granted priority review for the New Drug Application for TLX101-CDx, (Pixclara® ), Telix’s PET agent for the imaging of glioma. The application has been designated a PDUFA goal date of 26 April 2025, paving the way for a U.S. commercial launch in 2025.* There is a critical unmet need to improve the diagnosis and management of gliomas, which are the most common primary brain tumours of the central nervous system. With low survival rates and the need to make rapid decisions, precision imaging is paramount. Subject to regulatory approval, TLX101-CDx has the potential to address this need, enabling patients in the U.S. to receive greater clarity in their diagnosis and treatment decision making. Read more on our website here: https://lnkd.in/gTMURRzr TLX101-CDx has not received a marketing authorisation in any jurisdiction. *Subject to FDA marketing authorisation approval.

And the winner of the 2024 European Association of Nuclear Medicine (EANM) Sanjiv Sam Gambhir Award is… Grace Keane from UMC Utrecht in the Netherlands! Congratulations Grace on your win, and best of luck for your upcoming visitorship at Stanford University. Thanks to EANM for the opportunity to support the next generation of scientists and physicians through this award, in memory of a pioneer in nuclear medicine and molecular imaging. Brilliantly hosted and moderated by Sophie Veldhuijzen van Zanten and Joshua James M., with Simone Dalm, Andrei Iagaru, Stefano Fanti, and Anna Maria Karlberg making up the jury. See you next year! 🔗 Learn more about the award here: https://lnkd.in/daRv7rJu 📸 Check out the EANM photo album here (© Faistauer Photography): https://lnkd.in/eDSV7dNs #EANM24 #SamGambhirAward #NuclearMedicine

Telix is excited to support the 3rd annual #TackleCancerChallenge, a global movement organised by the Oncidium foundation to raise vital awareness about #Radiotheranostics in #CancerCare. Between now and November 3, join us from anywhere in the world by downloading the application: https://lnkd.in/eF4CuAaS Whether you are walking, running, swimming, cycling, or participating in any other physical activity, your efforts and financial contribution will help amplify awareness and support cancer patients and the advancement of this groundbreaking technology. And if you are at #EANM2024, join the team at 6:45 AM tomorrow for a morning exercise: walk or run - see you there! 🏃🚴♀️🏊

Telix is live at #EANM24 in Hamburg! Come and meet the team at booth #H29 to learn about our extensive theranostic pipeline and opportunities for collaboration. More on Telix at EANM here: https://lnkd.in/gsEB6NTd

Join Telix at EANM in Hamburg this Sunday for our hosted symposium, ‘Does size matter in targeted radionuclide therapies?’ The event features 5 internationally renowned key opinion leaders sharing their perspectives on the pros and cons of small molecule- and antibody-based approaches in radiopharmaceuticals. Don’t miss this fascinating discussion. More information on the symposium can be found on our website here: https://lnkd.in/gsEB6NTd #EANM2024

Telix has publicly filed a Form 20-F registration statement with the United States Securities and Exchange Commission (SEC) relating to a proposed listing of American Depository Shares, representing the Company’s ordinary shares, on the Nasdaq Stock Market (Nasdaq). The proposed Nasdaq listing is expected to be established as a Level II American Depositary Receipt (ADR) program, enabling streamlined and simplified access to Telix shares by the U.S. market. Read more on our website: https://lnkd.in/gPHUTGB9 There can be no assurance as to the occurrence, timing and/or completion of the proposed listing. This does not constitute an offer to sell or the solicitation of an offer to buy any securities of Telix.

Telix today provides a revenue and business update for Q3 2024. Unaudited total revenue for the quarter exceeded AU$200 million for the first time, primarily generated from sales of Telix’s prostate cancer imaging product Illuccix® in the Precision Medicine business unit. Telix continues to make excellent progress across multiple late-stage assets in our therapeutic pipeline, while preparing to commercialise three new imaging agents within our precision medicine portfolio. Telix also announced the acquisition of RLS, America’s only Joint Commission-accredited radiopharmacy network, in support of the Company’s strategy to further expand its North American manufacturing footprint. For more details on our Q3 2024 results, visit: https://bit.ly/3BNPAPI